Valeur en termes de données probantes des informations ... - KCE

More documents

Recommendations

Info

2 Written information from pharmaceutical companies KCE reports 55 4.3 METHODOLOGY......................................................................................................................................40 4.3.1 Choice of domain...........................................................................................................................40 4.3.2 Choice of material..........................................................................................................................42 4.3.3 Assessment of advertisements ....................................................................................................42 4.3.4 Analysis of advertisements ...........................................................................................................42 4.3.5 8 steps in the content analysis.....................................................................................................42 4.4 RESULTS.......................................................................................................................................................48 4.4.1 Number of analyses .......................................................................................................................48 4.4.2 Pharmaceutical companies............................................................................................................51 4.4.3 Presentation of claims ...................................................................................................................52 4.4.4 Tables and graphs...........................................................................................................................52 4.4.5 Claims ...............................................................................................................................................52 4.4.6 Outcome measures in clinical claims .........................................................................................54 4.4.7 References in advertisements......................................................................................................55 4.4.8 Linking the claims with the references ......................................................................................56 4.4.9 Final classification of the advertisement ....................................................................................57 4.4.10 Lacking information........................................................................................................................60 4.5 DISCUSSION...............................................................................................................................................60 4.5.1 Strengths and weaknesses of this study.....................................................................................60 4.5.2 Principal findings .............................................................................................................................60 4.5.3 Too little or too much? ................................................................................................................63 4.6 KEY MESSAGES...........................................................................................................................................64 5 QUALITATIVE APPROACH ....................................................................................... 65 5.1 INTRODUCTION......................................................................................................................................65 5.2 OBJECTIVES OF THE FOCUS GROUP INTERVIEWS......................................................................65 5.3 METHODOLOGY......................................................................................................................................65 5.4 RESULTS.......................................................................................................................................................67 5.4.1 Participants, moderation of interviews and atmosphere .......................................................67 5.4.2 What is written information according to participants and why do they use it? .............68 5.4.3 Need of written EBM information..............................................................................................71 5.4.4 Need of written information other than EBM information...................................................74 5.4.5 Presentation of written information ..........................................................................................79 5.4.6 Reliability..........................................................................................................................................83 5.4.7 Participants perceptions of marketing techniques of pharmaceutical companies.............84 5.4.8 Additional suggestions for improvement of written information ........................................92 5.5 DISCUSSION AND CONCLUSIO.........................................................................................................99 5.5.1 Strengths and weaknesses of the study.....................................................................................99 5.5.2 Principal findings ...........................................................................................................................100 5.6 KEY MESSAGES.........................................................................................................................................104 6 DISCUSSION AND CONCLUSIONS.......................................................................105 6.1 PRINCIPAL FINDINGS ...........................................................................................................................105 6.1.1 Global strategy of marketing......................................................................................................105 6.1.2 Semantics of pharmaceutical publicity versus information ..................................................105 6.1.3 Evidence based value ...................................................................................................................106 6.1.4 Reliability of advertisements ......................................................................................................107 6.1.5 Minimum information needed in advertisements..................................................................107 6.1.6 How to make therapeutic decisions?.......................................................................................107 6.1.7 Regulations and laws....................................................................................................................108 6.1.8 Suggestions for improvement....................................................................................................108 7 RECOMMENDATIONS ..............................................................................................110 7.1 SUGGESTIONS TOWARDS HEALTH CARE POLICY MAKERS.................................................110 7.1.1 Recommendations concerning the pharmaceutical companies..........................................110
KCE reports 55 Written information from pharmaceutical companies 3 7.1.2 Recommendations concerning the government....................................................................110 7.1.3 Recommendations concerning independent information sources.....................................111 7.1.4 Recommendations concerning the universities .....................................................................111 7.1.5 Recommendations concerning health professionals.............................................................111 7.2 NEED FOR FURTHER RESEARCH......................................................................................................112 8 REFERENCES...............................................................................................................113 9 APPENDICES...............................................................................................................116
Page 1 and 2: Valeur en termes de données proban
Page 3 and 4: Valeur en termes de données proban
Page 5 and 6: KCE Reports 55B Informations écrit
Page 13: KCE Reports 55B Informations écrit
Page 18 and 19: 4 Written information from pharmace
Page 24 and 25: 10 Written information from pharmac
Page 36 and 37: 22 EB content of written informatio
Page 66 and 67:
52 Written information from pharmac
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
100 Written information from pharma
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Dépôt légal : D/2007/10.273/13
Page 176:
35. Etude relative aux coûts poten
show all

Valeur en termes de données probantes des informations ... - KCE

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?